Alexa Fluor® 647 Mouse Anti-Human CD186 (CXCR6) Antibody (S-3884)

CXCR6 (C-X-C motif chemokine receptor 6), also known as STRL33 and T-lymphocyte-expressed seven-transmembrane domain receptor (TYMSTR), is a G protein-coupled receptor (GPCR) that specifically binds to its unique ligand CXCL16, a transmembrane chemokine that can also be cleaved to function as a soluble chemokine. CXCR6 is predominantly expressed on memory/effector T cells, natural killer T (NKT) cells, natural killer (NK) cells, and plasma cells, playing critical roles in immune cell trafficking, adhesion, and activation. The CXCR6-CXCL16 axis is essential for the recruitment and positioning of immune cells in various tissues, particularly in the liver, spleen, and inflamed sites, and has been implicated in numerous pathological conditions including chronic inflammation, autoimmune diseases, infectious diseases, and cancer. In oncology, CXCR6 expression on tumor-infiltrating lymphocytes (TILs) is associated with improved prognosis in certain cancers, while its expression on tumor cells can promote metastasis and disease progression. The receptor signals primarily through Gαi proteins, activating downstream pathways such as PI3K/AKT, MAPK/ERK, and calcium mobilization, thereby regulating cell migration, survival, and proliferation. Given its selective expression on activated immune cells and its involvement in disease pathogenesis, CXCR6 represents an attractive therapeutic target for immunomodulatory strategies and precision medicine approaches.